EMA Authorised: Yesintek (ustekinumab) — Biosimilar Collaborations Ireland Limited

View source ↗

Summary

Yesintek (ustekinumab) from Biosimilar Collaborations Ireland Limited has been authorised by the EMA for psoriasis, psoriatic arthritis, and Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• YESINTEK (USTEKINUMAB)

Snippet

Status: Authorised. Therapeutic area: Psoriasis;Arthritis, Psoriatic;Crohn Disease. MAH: Biosimilar Collaborations Ireland Limited. Decision date: 21/05/2026